MCF7/182R-1 Cell Line

A human fulvestrant-resistant breast cancer model used to study endocrine resistance, oestrogen receptor signalling, and targeted therapy development. Save 30% on this cell line this summer. Use code SUM26CELL at checkout.

Contributors

Inventor Institute
Anne Lykkesfeldt Danish Cancer Society
SKU: 152104
Product description: The MCF7/182R-1 Cell line is a breast cancer cell line resistant to fulvestrant (Faslodex). The MCF7/182R-1 cell line is a human breast cancer cell line established from a clone of MCF7/S0.5 cells. The cellular classification is epithelial, and their shape is polygonal. Treatment with the steroidal anti-estrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, resistance will inevitably occur also for fulvestrant. Clarification of the molecular changes associated with the resistant growth is needed to find targeted treatments to resistant tumour cells and treatments that can inhibit or delay the emergence of resistance.
Alternate name: MCF-7/182R-1
Gender: Female
Production details: The MCF7/182R-1 cell line has been established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal antiestrogen ICI 182,780 in 100 nM concentration, see Lykkesfeldt et al 1995. The MCF-7/182R-1 cells can be maintained continuously in growth medium with 100 nM fulvestrant.
Additional notes: Upon withdrawal of fulvestrant, the cells express ER alpha, although at a reduced level compared to the parental MCF7/S0.5 cell line. The MCF7/182R-1 cells do not express progesterone receptor. The MCF7/182R-1 cells express increased level of EGFR, phosphorylated EGFR and phosphorylated ErbB3 and reduced level of ErbB4 compared to the parental MCF7/S0.5 cells.
Cellosaurus ID: CVCL_1D40
Parental cell line: MCF7 S0.5
Disease: Cancer
Cat. #: 152104
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Cancer types: Breast cancer
Research Fields: Cancer; Drug development
Organism: Human
Tissue: Breast
Gender: Female
Model: Cancer cell line
Growth properties: Adherent
Cancer Types In Detail: Breast cancer;Fulvestrant resistant
Primary citation: Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-534. PMID: 7759159.
Format: Frozen
Shipping conditions: Dry ice
Growth medium: Phenol red free DMEM/F12 (1:1) supplemented with 1% FCS, Glutamax 2.5 mM and 6 ng/ml insulin. Supplemented with 100nM fulvestrant to maintain resistance.
Subculture routine: After thawing, dilute the cell suspension with sufficient medium and distribute 5 mL each into T25 flasks to achieve a seeding density of 0.5-1.0 x 10^4 / cm2. Place in a 37°C, 5% CO₂ incubator. Change medium after 24 hours to remove residual DMSO and then every 2-3 days. Subculture routine: Split 1:30 weekly with Trypsin-EDTA for detachment at 37 °C for 5 minutes. Please also see detailed protocol within the Product Datasheet in the Documentation section below.
Temperature: 37° C
Atmosphere: 5% CO2
Storage medium: 10% DMSO in FCS.
References:

Thrane et al. 2014. Oncogene. 34(32):4199-4210. PMID: 25362855.

Frogne et al. 2008. Breast Cancer Res Treat. 114(2):263-275. PMID: 18409071.

Frankel et al. 2006. Breast Cancer Res Treat. 104(2):165-179. PMID: 17061041.

Frogne et al. 2005. Endocr Relat Cancer. 12(3):599-614. PMID: 16172194.

Bradshaw et al. 2004. Curr Med Chem. 11(8):1009-1021. PMID: 15078163.

Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-534. PMID: 7759159.

Images

View Gallery
MCF7 182R-1 Cell Line. Early log phase. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC)

Related Tools for Cell lines

Cat. # Tool Name
152103 MCF7/164R-7 Cell Line Key Info View Tool
152105 MCF7/182R-6 Cell Line Key Info View Tool
152106 MCF7/182R-7 Cell Line Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.